权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER

克服胰腺癌治疗的间质障碍

基本信息

批准号：
10682621
负责人：
Sunil R Hingorani
金额：
$ 49.8万
依托单位：
UNIVERSITY OF NEBRASKA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-11 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10682621
关键词：
Ablation Adhesions Animal Model Architecture Behavior Biochemical Biology Biophysics Blood Vessels CD44 Antigens CD44 gene Cancer Etiology Cell Adhesion Molecules Cells Cessation of life Characteristics Chemicals Clinical Clinical Trials Complex Country Development Diffusion Disease Disease Resistance Drug Kinetics Drug resistance Engineering Epithelial Cells Epithelium Evolution Fostering Generations Genetic Genetic Engineering Glean Glycosaminoglycans Grant Growth HMMR gene Histopathology Hyaluronan ICAM1 gene Immune Immunoglobulin Class Switching Immunologics Immunosuppression In Vitro Incidence Investigation Knowledge Laboratories Learning Liquid substance Malignant Neoplasms Malignant neoplasm of pancreas Mechanics Mediating Minority Molecular Mutate Neoplasm Metastasis Normal tissue morphology Organ Pancreatic Ductal Adenocarcinoma Paracrine Communication Pathogenesis Patients Penetration Perfusion Pharmaceutical Preparations Physiology Process Prognosis Property Proteins Proteoglycan Reaction Resistance Role Sea Series Signal Pathway Signal Transduction Surface Syndrome T cell response Testing Therapeutic Therapeutic Agents Water Work autocrine cancer stem cell cell type design effector T cell human disease hypoperfusion improved interstitial mortality neoplastic cell novel novel therapeutic intervention novel therapeutics pancreatic cancer cells pancreatic cancer model paracrine pharmacokinetics and pharmacodynamics pressure prevent programs receptor therapy resistant tumor

项目摘要

PROJECT SUMMARY Pancreatic ductal adenocarcinomas (PDA) are unrivaled in their lethality. PDAs have the highest 1- year, 5-year, and 10-year mortalities of any cancer and are expected to become the second-leading cause of cancer-related death by 2030. An invasive PDA represents the coordinated evolution of cell- intrinsic and extrinsic processes and capabilities that subvert and repurpose the dictums of normal tissue composition, architecture, and physiology to foster unbridled growth and colonization. This new organizational entity is constructed largely at the behest of the mutated epithelial cell. The resulting PDA neo-organ contains a minority of tumor epithelial cells amidst a heterogeneous sea of non- epithelial cells; a complex interstitial stew of proteins, proteoglycans and glycosaminoglycans, together with both freely mobile and complexed water; and a paucity of vessels that otherwise resemble a normal vasculature in lacking fenestrae or interendothelial junctions, but that are collapsed under intense interstitial pressures. We have undertaken a systematic exploration of the cell autonomous and non-cell autonomous processes that drive PDA pathogenesis and resistance. We have developed genetically engineered animal models that faithfully recapitulate the clinical syndrome, metastatic behavior, histopathology and molecular features of the human disease as primary platforms to both uncover critical principles of disease biology and to rigorously test strategies to overcome them. Through such investigations we have identified unusually high concentrations of intratumoral hyaluronan (HA) as the primary culprit in the extraordinarily elevated interstitial pressures in PDA that, in turn, cause the vascular collapse and hypoperfusion characteristic of this disease. The stromal barrier to perfusion also serves as a primary mechanism of drug resistance in limiting the penetration of systemically delivered agents. We have additionally identified multiple mechanisms of immune suppression that prevent the development of an endogenous effector T cell response. Collectively, these unique aspects of stromal biology in PDA conspire to create a drug- and immune-privileged sanctuary for unimpeded growth of the pancreas cancer cell. Very recently, we have elaborated strategies to overcome critical aspects of these physical and immunological barriers to therapy revealing a perhaps unexpected degree of vulnerability once the barriers are breached. We describe a series of continuing investigations into this overarching strategy of stromal re-engineering to build upon the significant inroads made – and the important lessons learned – in the hopes of radically transforming the approach and prognosis for this formidable disease.

项目总结胰腺导管腺癌(PDA)的致命性是无与伦比的。掌上电脑拥有最高的1- 年、5年和10年任何癌症的死亡率，预计将成为第二大到2030年与癌症相关的死亡原因。侵袭性的PDA代表了细胞- 颠覆和改变正常标准的内在和外在的过程和能力组织组成、结构和生理学，以促进无节制的生长和定居。这是一项新的组织实体在很大程度上是在突变的上皮细胞的要求下构建的。由此产生的 PDA新生器官包含少数肿瘤上皮细胞，在异质的非上皮细胞；由蛋白质、蛋白多糖和糖胺多糖组成的复杂的间质炖锅有自由流动的水和复杂的水；以及稀少的容器，否则就像一个缺乏窗孔或内皮细胞连接的正常血管系统，但在强烈的间质压力。我们对细胞的自主性进行了系统的探索推动PDA发病和耐药的非细胞自主过程。我们已经开发出基因工程动物模型忠实地概括了临床综合征，转移性人类疾病的行为、组织病理学和分子特征作为两者的主要平台发现疾病生物学的关键原理，并严格测试克服这些原理的策略。通过这样的调查，我们发现了肿瘤内异常高浓度的透明质酸(HA)是PDA间质压力异常升高的罪魁祸首，进而导致本病特有的血管塌陷和低灌注率。《间质》灌流屏障也是耐药的一个主要机制，限制了药物的渗透系统交付的特工。此外，我们还确定了多种免疫机制抑制，防止内源性效应T细胞反应的发展。总而言之， PDA间质生物学的这些独特方面共同创造了一种药物和免疫特权胰腺癌细胞不受阻碍地生长的避难所。最近，我们已经详细阐述了克服这些治疗的生理和免疫障碍的关键方面的策略一旦障碍被突破，就会暴露出可能出乎意料的脆弱程度。我们描述了一种对基质再造这一总体战略的一系列持续调查，以此为基础取得的重大进展--以及吸取的重要教训--希望从根本上改变这一可怕疾病的治疗方法和预后。

项目成果

期刊论文数量（19）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

DOI：
10.1016/j.ccell.2015.09.022
发表时间：
2015-11-09
期刊：
Cancer cell
影响因子：
50.3
作者：
Stromnes IM;Schmitt TM;Hulbert A;Brockenbrough JS;Nguyen H;Cuevas C;Dotson AM;Tan X;Hotes JL;Greenberg PD;Hingorani SR
通讯作者：
Hingorani SR

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.

DOI：
10.1158/0008-5472.can-11-1433
发表时间：
2013-06-01
期刊：
Cancer research
影响因子：
11.2
作者：
Spivak-Kroizman TR;Hostetter G;Posner R;Aziz M;Hu C;Demeure MJ;Von Hoff D;Hingorani SR;Palculict TB;Izzo J;Kiriakova GM;Abdelmelek M;Bartholomeusz G;James BP;Powis G
通讯作者：
Powis G

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.